CTOs on the Move

Genomic Health

www.genomichealth.com

 
Genomic Health, Inc. (NASDAQ: GHDX) is the world`s leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient`s journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Craig Guinasso
Associate Director - Information Security Profile
Dave Green
Senior Director of Information Technology Profile
Mike Vedda
Chief Information Officer Profile

Similar Companies

NewLeaf Symbiotics

NewLeaf Symbiotics® is at the forefront of sustainable agriculture technology, with a singular focus on the identification, development and commercialization of the beneficial microbes called pink pigmented facultative methylotrophs (M-trophs). This new class of agricultural microbes is helping transition agricultural products and production to deliver better quality crops, with less impact on the environment — a win-win for growers and those of us who depend on their success.

Axial Therapeutics

We are harnessing the #gut brain axis & the #CNS to develop a new class of therapeutics for people with neurological diseases & disorders

Octave Bioscience

Octave is developing a comprehensive, first-in-class Care Management Platform.

MediGene

MediGene, Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seres Health

Seres Health is a clinical-stage therapeutics company focused on discovering and developing Ecobiotic® therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome.  Founded by the Flagship Ventures innovation foundry, VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases. Seres recently announced a research alliance with Mayo Clinic and has received over $20 million in funding to date.